Institutional Investors Lead Shift in Alimera Sciences Inc (NASDAQ:ALIM) Sentiment

Alimera Sciences, Inc. (NASDAQ:ALIM) Logo

Sentiment for Alimera Sciences Inc (NASDAQ:ALIM)

Alimera Sciences Inc (NASDAQ:ALIM) institutional sentiment decreased to 1 in 2018 Q4. Its down -1.25, from 2.25 in 2018Q3. The ratio dropped, as 11 investment managers increased or started new stock positions, while 11 sold and reduced their stakes in Alimera Sciences Inc. The investment managers in our partner’s database now possess: 28.69 million shares, down from 29.16 million shares in 2018Q3. Also, the number of investment managers holding Alimera Sciences Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 5 Increased: 6 New Position: 5.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $66.71 million. It focuses on diseases affecting the back of the eye or retina. It has a 2.95 P/E ratio. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

The stock increased 0.16% or $0.0015 during the last trading session, reaching $0.94. About 5,407 shares traded. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 7.87% since May 8, 2018 and is downtrending. It has underperformed by 12.24% the S&P500.

Analysts await Alimera Sciences, Inc. (NASDAQ:ALIM) to report earnings on May, 9. They expect $-0.05 EPS, up 37.50 % or $0.03 from last year’s $-0.08 per share.

Armistice Capital Llc holds 0.38% of its portfolio in Alimera Sciences, Inc. for 6.94 million shares. Venbio Select Advisor Llc owns 6.24 million shares or 0.27% of their US portfolio. Moreover, Jw Asset Management Llc has 0.22% invested in the company for 413,300 shares. The New York-based Knott David M has invested 0.13% in the stock. B. Riley Wealth Management Inc., a Tennessee-based fund reported 101,906 shares.

Alimera Sciences, Inc. (NASDAQ:ALIM) Ratings Coverage

Ratings analysis reveals 100% of Alimera’s analysts are positive. Out of 2 Wall Street analysts rating Alimera, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2 while the high is $3.05. The stock’s average target of $2.90 is 208.51% above today’s ($0.94) share price. ALIM was included in 7 notes of analysts from November 27, 2018. As per Thursday, March 7, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the shares of ALIM in report on Wednesday, February 20 with “Buy” rating. The firm earned “Buy” rating on Tuesday, March 26 by H.C. Wainwright. The firm has “Buy” rating given on Monday, March 25 by FBR Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, November 27.

More notable recent Alimera Sciences, Inc. (NASDAQ:ALIM) news were published by: Zacks.com which released: “Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know – Zacks.com” on February 20, 2019, also Prnewswire.com with their article: “Alimera Sciences Announces 8 ILUVIENĀ® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting – PR Newswire” published on July 11, 2018, Seekingalpha.com published: “Alimera’s ILUVIEN approved in Kuwait – Seeking Alpha” on March 21, 2019. More interesting news about Alimera Sciences, Inc. (NASDAQ:ALIM) were released by: Nasdaq.com and their article: “5 Top Multibagger Biotech Stocks to Buy in the 2nd Half – Nasdaq” published on July 11, 2017 as well as Seekingalpha.com‘s news article titled: “Tuesday’s Bio-Pharma Watch List – Seeking Alpha” with publication date: March 27, 2012.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.